Ricerca Granted DEA License
{Businesswire via BioPortfolio} Ricerca Biosciences, an industry-leading, integrated preclinical
contract research organization (CRO) providing services to the chemical and biopharmaceutical
industries, is pleased to announce services it can now provide under its United States Drug Enforcement
Administration (DEA) license.
Ricerca possesses a current DEA license, which allows Ricerca to handle multiple kilos of
agency-controlled Schedule II-V substances for research and development projects at its Concord, Ohio,
facility. This would include preparation of Phase I to Phase II clinical bulk API supplies.
As the mission of the DEA is to enforce the controlled substance laws and regulations of the United
States, it only licenses highly reputable companies to handle and produce controlled substances. Crucial
criteria distinguished by the government agency include documented accountability of material usage
and disposal, secure storage and strong ICH Q7A compliance. In addition, a team of experienced
chemists to execute the complex synthetic routes, as well as an experienced analytical chemistry
group to perform IPC testing and method development work are also a necessity.
“We have the ability to move forward on clients’ R&D projects that require a DEA license
with no delay,― stated Rich Donaldson, Ph.D, vice president of chemical development at Ricerca.
“We are proud of our track record and dedication to excellence supporting this license, and more
importantly, the license signifies our commitment to rapidly moving projects forward.― Dr. Donaldson is
responsible for process chemistry, radiosynthesis, process development and engineering and analytical
chemistry.
Ricerca offers a unique spectrum of services for the areas of agrochemical registration,
environmental analysis and preclinical discovery and development for biopharmaceutical registration.
About Ricerca Biosciences
Page 1/2
Ricerca Biosciences offers a comprehensive suite of discovery and preclinical services to
support drug candidates from discovery through IND on a global scale, including capabilities in discovery
and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up, IND-enabling
toxicology, molecular profiling, pharmacology/DMPK and drug safety assessment services. With facilities
in Concord, Ohio; Bothell, Washington; Taipei, Taiwan; and Lyon, France, Ricerca offers scientific
excellence through reliable, cost-effective strategies to accelerate your drug discovery programs.
http://www.bioportfolio.com/news/article/3321/Ricerca-Granted-Dea-License.html
Page 2/2